Zohar Zisapel - Amdocs Independent Director

DOX Stock  USD 85.04  0.67  0.78%   

Director

Mr. Zohar Zisapel serves as Independent Director of Amdocs Limited. He was a director of Amdocs since 2008 and is the Chairman of the Technology and Innovation Committee. Mr. Zisapel cofounded RAD Data Communications Ltd., a privatelyheld voice and data communications company and part of the RAD Group, a family of independent networking and telecommunications companies, and was its CEO from 1982 until 1998 and Chairman from 1998 until 2012. Mr. Zisapel also serves as chairman of Ceragon Networks Ltd. and as a director of Radcom Ltd., both public companies traded on Nasdaq, and on the boards of directors of several privatelyheld companies. Mr. Zisapel served as chairman of the Israel Association of Electronic Industries from 1998 until 2001 since 2008.
Age 68
Tenure 16 years
Professional MarksPh.D
Address 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141
Phone314 212 7000
Webhttps://www.amdocs.com
Zisapel received an Honorary Doctorate from the Technion — Israel Institute of Technology, and he is teaching Entrepreneurship at the Tel Aviv University.

Amdocs Management Efficiency

The company has Return on Asset of 0.071 % which means that on every $100 spent on assets, it made $0.071 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1562 %, implying that it generated $0.1562 on every 100 dollars invested. Amdocs' management efficiency ratios could be used to measure how well Amdocs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.10 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Amdocs' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 307 M in 2024, whereas Total Assets are likely to drop slightly above 4.5 B in 2024.
The company has 807.31 M in debt with debt to equity (D/E) ratio of 0.23, which may show that the company is not taking advantage of profits from borrowing. Amdocs has a current ratio of 1.57, which is typical for the industry and considered as normal. Debt can assist Amdocs until it has trouble settling it off, either with new capital or with free cash flow. So, Amdocs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amdocs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amdocs to invest in growth at high rates of return. When we think about Amdocs' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Chi KanGlobal Blue Group
N/A
Shikhar GhoshWex Inc
62
Janice ObuchowskiCSG Systems International
66
Regina SommerWex Inc
62
Aldo PolakEvertec
43
James UnruhCSG Systems International
77
Jason ReamQualys Inc
46
Louis SimpsonVeriSign
81
Kristi RogersQualys Inc
48
Teresita RosadoEvertec
62
Donald SmithCSG Systems International
75
Todd HeadleyQualys Inc
54
Stephen SmithF5 Networks
60
Kirk PondWex Inc
73
Timothy TomlinsonVeriSign
68
David BarnesCSG Systems International
56
Rajan NaikCSG Systems International
46
David SchaefferCyberArk Software
57
Marwan FawazCSG Systems International
55
Kim PerdikouCyberArk Software
56
Teresita LoubrielEvertec
64
Amdocs Limited, through its subsidiaries, provides software and services worldwide. Amdocs Limited was founded in 1988 and is headquartered in Saint Louis, Missouri. Amdocs operates under SoftwareInfrastructure classification in the United States and is traded on NASDAQ Exchange. Amdocs (DOX) is traded on NASDAQ Exchange in USA. It is located in 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141 and employs 29,000 people. Amdocs is listed under IT Consulting & Other Services category by Fama And French industry classification.

Management Performance

Amdocs Leadership Team

Elected by the shareholders, the Amdocs' board of directors comprises two types of representatives: Amdocs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amdocs. The board's role is to monitor Amdocs' management team and ensure that shareholders' interests are well served. Amdocs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amdocs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joshua Sheffer, CEO President
Darcy Antonellis, Head Media
Oren Marmur, Head Network
Richard LeFave, Independent Director
Matthew Smith, Corporate Secretary
John MacDonald, Director
Idit Aronsohn, Inclusion Responsibility
Zohar Zisapel, Independent Director
Simon Olswang, Independent Director
Anshoo Gaur, Division President of Amdocs Devel. Center India Pvt Ltd
Elizabeth McDermon, Secretary and VP of Corporate Strategy of Amdocs Inc.
Giora Yaron, Director
Gary Miles, Chief Officer
Shuky Sheffer, Senior Vice President and President of Customer Business Group, Amdocs Management Limited
Robert Minicucci, Independent Chairman of the Board
Mustafa Oyumi, Head Strategy
Clayton Christensen, Director
James Kahan, Independent Director
Rajat Raheja, Division President Amdocs Development Center India Pvt. Ltd
Avishai Sharlin, GM President
Adrian Gardner, Independent Director
Tamar RapaportDagim, Senior Vice President and CFO of Amdocs Management Limited
John McLennan, Independent Director
Matt Smith, IR Contact Officer
Julian Brodsky, Independent Director
Anthony Goonetilleke, Group Strategy
Eli Gelman, Director, Member of Technology and Innovation Committee, CEO of Amdocs Management Limited and President of Amdocs Management Limited

Amdocs Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amdocs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Amdocs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.

Moving against Amdocs Stock

  0.67EGIO Edgio Inc TrendingPairCorr
  0.64NN Nextnav Acquisition Corp Financial Report 8th of May 2024 PairCorr
  0.58VERI Veritone Financial Report 7th of May 2024 PairCorr
  0.55GB Global Blue GroupPairCorr
The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs to buy it.
The correlation of Amdocs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amdocs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amdocs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amdocs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amdocs Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Amdocs Stock analysis

When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stocks Directory
Find actively traded stocks across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.18
Dividend Share
1.74
Earnings Share
4.68
Revenue Per Share
41.665
Quarterly Revenue Growth
0.05
The market value of Amdocs is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amdocs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.